Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schering-Plough Research Institute has joined a scientific collaboration of pharmaceutical firms organized by Hurel Corporation to develop an alternative technology to animal testing.
Subscribe to our email newsletter
Under the agreement, Schering-Plough Research Institute (SPRI), the R&D arm of Schering-Plough, will provide both scientific guidance and funding as Hurel continues its one-year R&D program aimed at validating and developing its microfluidic, ‘human-on-a-chip’ cell-based assay platform technology.
Johnson & Johnson Pharmaceutical R&D LLC (J&JPRD) was the first pharmaceutical firm to enter the joint scientific collaboration (JSC), which commenced R&D operations in January 2006. Through the collaboration, SPRI, J&JPRD, and Hurel will collectively advance the development of Hurel’s proprietary technology, towards the ultimate goal of making Hurel’s products and services ready for widespread use.
“Schering-Plough is deeply committed to seeking out and developing new technologies that will enable pharmaceutical scientists to rely less on animal testing as they search for and create new medicines,” said Dr Catherine Strader, executive vice president for discovery research at SPRI. “We look forward to collaborating with Hurel and other participants in the JSC to address the scientific and technical issues with this exciting new approach.”
Hurel is currently in discussion with several additional, large pharmaceutical firms with respect to their joining the JSC.